pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

241 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT776Endpoints579BioPharma Dive223onclive165Fierce Biotech54BioSpace52raps22
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6
  • <![CDATA[Combination and Sequencing Strategies in Metastatic Castration-Resistant Prostate Cancer]]>
    <![CDATA[Dr. Pedro Barata and Dr. Johann De Bono discuss ongoing questions surrounding combination approaches and optimal sequencing strategies for radiopharmaceutical therapies in metastatic castr…
    onclive · 2mo ago↗ source
  • <![CDATA[Treatment Sequencing in Metastatic Castration-Resistant Prostate Cancer]]>
    <![CDATA[Dr. Johann De Bono and Dr. Pedro Barata discuss the evolving role of treatment sequencing and patient selection for radiopharmaceuticals in metastatic castration-resistant prostate cancer…
    onclive · 2mo ago↗ source
  • <![CDATA[Patient Selection for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Cancer]]>
    <![CDATA[Dr. Pedro Barata and Dr. Johann De Bono discuss how patient selection and disease characteristics influence the use of radiopharmaceuticals in metastatic castration-resistant prostate canc…
← prev
page 6 of 10
next →
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
onclive · 2mo ago↗ source
  • <![CDATA[Alpha-Emitting Therapies in Metastatic Castration-Resistant Prostate Cancer]]>
    <![CDATA[Dr. Johann De Bono and Dr. Pedro Barata discuss the evolving role of alpha-emitting radiopharmaceutical therapies in metastatic castration-resistant prostate cancer (mCRPC), with a focus o…
    onclive · 2mo ago↗ source
  • <![CDATA[Consensus Recommendations Address Key Controversies in Lymphoma Management]]>
    <![CDATA[Alexey Danilov, MD, PhD, and Tycel Phillips, MD, highlight key consensus viewpoints in lymphoma published from the 2025 Bridging the Gaps meeting.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Combination Radiopharmaceutical Approaches in Metastatic Castration-Resistant Prostate Cancer]]>
    <![CDATA[Dr. Pedro Barata and Dr. Johann De Bono discuss emerging combination strategies involving radiopharmaceuticals in metastatic castration-resistant prostate cancer (mCRPC), with a focus on t…
    onclive · 2mo ago↗ source
  • <![CDATA[Radiopharmaceutical Strategies in Metastatic Castration-Resistant Prostate Cancer]]>
    <![CDATA[Dr. Pedro Barata and Dr. Johann De Bono open the discussion by reviewing the evolving role of radiopharmaceuticals in metastatic castration-resistant prostate cancer (mCRPC) and outlining…
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Bockorny on the Rationale for Targeting CCR8 in Solid Tumors ]]>
    <![CDATA[Bruno B. Bockorny, MD, discusses the rationale for evaluating the anti-CCR8 antibody in a phase 1 trial in solid tumors. ]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Answering Key Clinical Questions About Esophageal Cancer Care: With Peter Enzinger, MD ]]>
    <![CDATA[Peter Enzinger, MD, answers common questions about the diagnosis and management of esophageal cancer in this clinician-focused FAQ interview.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[FDA Approval Insights: Brexu-Cel for Relapsed/Refractory MCL: With Luhua (Michael) Wang, MD]]>
    <![CDATA[Luhua (Michael) Wang, MD, discusses the implications of the FDA approval of brexu-cel for the treatment of adult patients with relapsed/refractory MCL. ]]>
    onclive · 2mo ago↗ source
  • <![CDATA[UCSF Receives Major Gift to Advance Research and Modernization]]>
    <![CDATA[Kathy Chiao and Ken Hao commit $100 million for major capital projects, cancer research, and innovation at UCSF — building on a recent $75 million gift to UC Davis for veterinary medicine.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Emerging Clinical Trials and Future Therapeutic Strategies in Recurrent Endometrial Cancer]]>
    <![CDATA[The panel surveys the clinical trial landscape and emerging therapeutic strategies for patients with recurrent endometrial cancer, particularly those who have progressed on frontline check…
    onclive · 2mo ago↗ source
  • <![CDATA[CLL-321 Trial Efficacy and Safety Results Analysis]]>
    <![CDATA[Phase 3 results: pirtobrutinib boosts PFS, delays next treatment after prior BTK therapy, and shows low cardiac toxicity.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[How Reimagined Research Endeavors Intersect With Dignified End-of-Life Care: With D. Ross Camidge, MD, PhD; and Charles D. Blanke, MD, FACP, FASCO ]]>
    <![CDATA[Drs Camidge and Blanke discuss Dr Blanke's career path from pioneering targeted cancer therapies to becoming a leading advocate for medical aid in dying.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[BRUIN CLL-321 Trial Impact and Treatment Selection]]>
    <![CDATA[Experts outline relapse workup in CLL, using PET-CT and biopsy for suspected Richter’s, plus resistance and TP53 testing to guide next therapy.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Biomarker-Driven Treatment Decisions and Managing Progression After Frontline Immunotherapy]]>
    <![CDATA[Upfront biomarker testing reshapes endometrial cancer care, guiding targeted and immune therapy—and exposing gaps in second-line options.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr McCann on the FDA Approval of Vepdegestrant for ESR1-Mutated, ER+ Advanced Breast Cancer]]>
    <![CDATA[Kelly Elizabeth McCann, MD, PhD, notes the role of vepdegestrant in the ESR1-mutated, ER-positive, HER2-negative advanced breast cancer treatment paradigm.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Honesty and Humor Provide Hope in Breast Cancer Survivorship: With Sara Nunnery, MD, MSCI; and Annie Bond]]>
    <![CDATA[Dr Nunnery and Annie Bond discuss breast cancer survivorship and patient advocacy.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[AUA and SUO Amend Advanced Prostate Cancer Guideline]]>
    <![CDATA[The AUA and SUO released the 2026 amendment to the Advanced Prostate Cancer Guideline.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Postow on an Ideal Post-ICI Monitoring Framework in Melanoma ]]>
    <![CDATA[Michael A. Postow, MD, discusses the importance of long-term multidisciplinary follow-up for patients with melanoma treated with ICIs.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Postow on the Timing of Delayed or Re-Emergent irAEs in Melanoma]]>
    <![CDATA[Michael A. Postow, MD, discusses the evolving understanding of ICIs in melanoma and the unique toxicity profiles associated with these agents.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Temple Health’s Fox Chase Cancer Center and Labcorp Collaborate to Test Ultra-Sensitive Blood-Based Assay for Early-Stage Lung Cancer Recurrence Risk]]>
    <![CDATA[A Fox Chase Cancer Center study will evaluate a tumor-informed, whole-genome sequencing–based test to assess recurrence risk in early-stage NSCLC.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[FDA Grants Breakthrough Therapy Designation to Emi-Le for Adenoid Cystic Carcinoma]]>
    <![CDATA[Emi-Le received breakthrough therapy designation from the FDA for the treatment of patients with locally advanced, recurrent or metastatic ACC.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[[177Lu]Lu-D-Dan-Phe-PSMA Demonstrates Manageable Safety and Early Efficacy mCRPC ]]>
    <![CDATA[[177Lu]Lu-D-Dan-Phe-PSMA showed early signals of safety and activity in mCRPC.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[FDA Issues Warning Regarding Risk of Secondary Primary Malignancies With Tazemetostat in Follicular Lymphoma, Epithelioid Sarcoma ]]>
    <![CDATA[The FDA issued a warning about the risk of secondary primary malignancies associated with tazemetostat in epithelioid sarcoma and follicular lymphoma. ]]>
    onclive · 2mo ago↗ source